Akero Therapeutics Inc (NASDAQ:AKRO) shares, rose in value on Friday, December 13, with the stock price down by -0.48% to the previous day’s close as strong demand from buyers drove the stock to $28.89.
Actively observing the price movement in the last trading, the stock closed the session at $29.03, falling within a range of $28.25 and $29.255. The value of beta (5-year monthly) was -0.26. Referring to stock’s 52-week performance, its high was $37.00, and the low was $15.32. On the whole, AKRO has fluctuated by -6.72% over the past month.
With the market capitalization of Akero Therapeutics Inc currently standing at about $2.02 billion, investors are eagerly awaiting this quarter’s results, scheduled for in January.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AKRO’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of AKRO currently trading nearly -6.04% and -5.98% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.69, while the 7-day volatility ratio is showing 4.01% which for the 30-day chart, stands at 4.98%. Furthermore, Akero Therapeutics Inc (AKRO)’s beta value is -0.23, and its average true range (ATR) is 1.45.
A comparison of Akero Therapeutics Inc (AKRO) with its peers suggests the former has fared considerably weaker in the market. AKRO showed an intraday change of -0.48% in last session, and over the past year, it grew by 42.04%%.
Data on historical trading for Akero Therapeutics Inc (NASDAQ:AKRO) indicates that the trading volumes over the past 10 days have averaged 0.47 and over the past 3 months, they’ve averaged 566.10K. According to company’s latest data on outstanding shares, there are 69.61 million shares outstanding.
Nearly 16.19% of Akero Therapeutics Inc’s shares belong to company insiders and institutional investors own 92.02% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.29 million shares as on 2024-11-29, resulting in a short ratio of 4.86. According to the data, the short interest in Akero Therapeutics Inc (AKRO) stood at 485.00 of shares outstanding as of 2024-11-29; the number of short shares registered in 2024-10-31 reached 3.82 million. The stock has risen by 23.73% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AKRO stock heading into the next quarter.
